References
- Martins SS, Sarvet A, Santaella-Tenorio J, et al. Changes in US lifetime heroin use and heroin use disorder: prevalence From the 2001-2002 to 2012-2013 National Epidemiologic Survey on Alcohol and Related Conditions. JAMA Psychiatry. 2017;74(5):445455.
- Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose Deaths-United States, 2000-2014. MMWR Morb Mortal Wkly Rep. 2016;64(50–51):1378–1382.
- Kandel DB, Hu MC, Griesler P, Wall M. Increases from 2002 to 2015 in prescription opioid overdose deaths in combination with other substances. Drug Alcohol Depen. 2017;178:501–511.
- O'Donnell JK, Halpin J, Mattson CL, Goldberger BA, Gladden RM. Deaths involving fentanyl, fentanyl analogs, and U-47700 - 10 states, July-December 2016. MMWR Morb Mortal Wkly Rep. 2017;66(43):1197–1202.
- Han B, Compton WM, Jones CM, Cai R. Nonmedical prescription opioid use and use disorders among adults aged 18 through 64 years in the United States, 2003-2013. JAMA. 2015;314(14):1468–1478.
- Kolodny A, Courtwright DT, Hwang CS, et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health. 2015;36(1):559–574.
- Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2016 National Survey on Drug Use and Health (HHS Publication No. SMA 17-5044, NSDUH Series H-52). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2017.
- Winkelman TNA, Chang VW, Binswanger IA. Health, polysubstance use, and criminal justice involvement among adults with varying levels of opioid use. JAMA Netw Open. 2018;1(3):e180558.
- Becker WC, Sullivan LE, Tetrault JM, Desai RA, Fiellin DA. Non-medical use, abuse and dependence on prescription opioids among U.S. adults: psychiatric, medical and substance use correlates. Drug Alcohol Depend. 2008;94(1–3):38–47.
- Wilens TE, Biederman J, Bredin E, et al. A family study of the high-risk children of opioid- and alcohol-dependent parents. Am J Addict. 2002;11(1):41–51.
- Bukten A, Skurtveit S, Gossop M, et al. Engagement with opioid maintenance treatment and reductions in crime: a longitudinal national cohort study. Addiction. 2012;107(2):393–399.
- Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction. 1998;93(4):515–532.
- Florence CS, Zhou C, Luo F, Xu L. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Med Care. 2016;54(10):901–906.
- Rhyan CN. The potential societal benefit of eliminating opioid overdoses, deaths, and substance use disorders exceeds $95 billion per year. https://altarum.org/sites/default/files/uploaded-publication-files/Research-Brief_Opioid-Epidemic-Economic-Burden.pdf. 2017. Accessed February 14, 2018.
- Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study. Ann Intern Med. 2018;169(3):137–145.
- Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Lintzeris N. Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database Syst Rev. 2016;(5):CD011117.
- Nielsen S, Larance B, Lintzeris N. Opioid agonist treatment for patients with dependence on prescription opioids. JAMA. 2017;317(9):967–968.
- Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2:CD002207.
- Wu LT, Zhu H, Swartz MS. Treatment utilization among persons with opioid use disorder in the United States. Drug Alcohol Depend. 2016;169:117–127.
- Substance Abuse and Mental Health Services Administration. Treatment Episode Data Set (TEDS): 2005-2015. National Admissions to Substance Abuse Treatment Services. BHSIS Series S-91, HHS Publication No. (SMA) 17-5037. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2017.
- Collins FS, Koroshetz WJ, Volkow ND. Helping to end addiction over the long-term: The research plan for the NIH HEAL Initiative. JAMA. 2018;320(2):129–130.
- Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105(8):e55–e63.
- Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction (Treatment Improvement Protocol #40). Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004.
- Knudsen HK, Havens JR, Lofwall MR, Studts JL, Walsh SL. Buprenorphine physician supply: Relationship with state-level prescription opioid mortality. Drug Alcohol Depend. 2017;173(Suppl 1):S55–S64.
- Altice FL, Bruce RD, Lucas GM, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: Results from a multisite study. Jaids-J Acq Imm Def. 2011;56:S22–S32.
- Stein BD, Pacula RL, Gordon AJ, et al. Where is buprenorphine dispensed to treat opioid use disorders? The role of private offices, opioid treatment programs, and substance abuse treatment facilities in urban and rural counties. Milbank Q. 2015;93(3):561–583.
- Dick AW, Pacula RL, Gordon AJ, et al. Growth in buprenorphine waivers for physicians increased potential access to opioid agonist treatment, 2002-11. Health Aff. 2015;34(6):1028–1034.
- Knudsen HK, Lofwall MR, Havens JR, Walsh SL. States' implementation of the Affordable Care Act and the supply of physicians waivered to prescribe buprenorphine for opioid dependence. Drug Alcohol Depend. 2015;157:36–43.
- Andrilla CHA, Moore TE, Patterson DG, Larson EH. Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: A 5-year update. J Rural Health. 2019;35(1):108–112.
- Wen H, Hockenberry JM, Borders TF, Druss BG. Impact of Medicaid expansion on Medicaid-covered utilization of buprenorphine for opioid use disorder treatment. Med Care. 2017;55(4):336–341.
- Clemans-Cope L, Epstein M, Kenney GM. Rapid growth in Medicaid spending on medications to treat opioid use disorder and overdose. https://web.archive.org/web/20170710140634/http://www.urban.org/sites/default/files/publication/91521/2001386-rapid-growth-in-medicaid-spending-on-medications-to-treat-opioid-use-disorder-and-overdose_3.pdf. 2017. Accessed August 24, 2017.
- Department of Health and Human Services. 42 CFR Part 8, RIN 0930-AA22, Medication assisted treatment for opioid use disorders. Fed Regist. 2016;81(131):44712–44739.
- Substance Abuse and Mental Health Services Administration. Understanding the final rule for a patient limit of 275. https://www.samhsa.gov/sites/default/files/programs_campaigns/medication_assisted/understanding-patient-limit275.pdf. 2016. Accessed July 18, 2018.
- Stein BD, Sorbero M, Dick AW, et al. Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment. JAMA. 2016;316(11):1211–1212.
- Huhn AS, Dunn KE. Why aren't physicians prescribing more buprenorphine? J Subst Abuse Treat. 2017;78:1–7.
- Andrilla CHA, Coulthard C, Patterson DG. Prescribing practices of rural physicians waivered to prescribe buprenorphine. Am J Prev Med. 2018;54(6S3):S208–S214.
- Rosenblatt RA, Andrilla CHA, Catlin M, Larson EH. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Ann Fam Med. 2015;13(1):23–26.
- Stein BD, Gordon AJ, Dick AW, et al. Supply of buprenorphine waivered physicians: The influence of state policies. J Subst Abuse Treat. 2015;48(1):104–111.
- Knudsen HK. The supply of physicians waivered to prescribe buprenorphine for opioid use disorders in the United States: A state-level analysis. J Stud Alcohol Drugs. 2015;76(4):644–654.
- Sommers BD, Gunja MZ, Finegold K, Musco T. Changes in self-reported insurance coverage, access to care, and health under the Affordable Care Act. J Am Med Assoc. 2015;314(4):366–374.
- Wen H, Druss BG, Cummings JR. Effect of Medicaid expansions on health insurance coverage and access to care among low-income adults with behavioral health conditions. Health Serv Res. 2015;50(6):1787–1809.
- Feder KA, Mojtabai R, Krawczyk N, et al. Trends in insurance coverage and treatment among persons with opioid use disorders following the Affordable Care Act. Drug Alcohol Depend. 2017;179:271–274.
- McKenna RM. Treatment use, sources of payment, and financial barriers to treatment among individuals with opioid use disorder following the national implementation of the ACA. Drug Alcohol Depend. 2017;179:87–92.
- US Census Bureau. Table 1. Annual Estimates of the Resident Population for the United States, Regions, States, and Puerto Rico: April 1, 2010 to July 1, 2018 (NST-EST2018-01). https://www.census.gov/data/datasets/time-series/demo/popest/2010s-state-total.html. 2018. Accessed February 13, 2019.
- United States Census Bureau. Census regions and divisions of the United States. https://web.archive.org/web/20150226213756/http://www.census.gov/geo/maps-data/maps/pdfs/reference/us_regdiv.pdf. 2015. Accessed February 26, 2015.
- Henry J. Kaiser Family Foundation. Status of state action on the Medicaid expansion decision. http://kff.org/health-reform/state-indicator/state-activity-around-expanding-medicaid-under-the-affordable-care-act/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D. Published 2016. Accessed September 21, 2016.
- Henry J. Kaiser Family Foundation. Uninsured rates for the nonelderly by age. https://www.kff.org/uninsured/state-indicator/rate×age/?dataView=1¤tTimeframe=1&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D. 2019. Accessed February 13, 2019.
- Henry J. Kaiser Family Foundation. Opioid overdose death rates and all drug overdose death rates per 100,000 population (age-adjusted). https://www.kff.org/other/state-indicator/opioid-overdose-death-rates/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D. 2017. Accessed January 23, 2018.
- Henry J. Kaiser Family Foundation. Individuals reporting needing but not receiving treatment for illicit drug use in the past year. https://www.kff.org/other/state-indicator/individuals-reporting-needing-but-not-receiving-treatment-for-illicit-drug-use-in-the-past-year/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D#notes. 2017. Accessed December 12, 2017.
- Rabe-Hesketh S, Skronkal A. Multilevel and Longitudinal Modeling Using Stata. Vol. 1. 3rd ed. College Station, TX: Stata Press; 2012.
- Mitchell MN. Interpreting and Visualizing Regression Models Using Stata. College Station, TX: Stata Press; 2012.
- Rogers EM. Diffusion of Innovations. 5th ed. New York, NY: Free Press; 2003.
- Ali MM, Teich JL, Mutter R. The role of perceived need and health insurance in substance use treatment: Implications for the Affordable Care Act. J Subst Abuse Treat. 2015;54:14–20.
- Huhn AS, Tompkins DA, Dunn KE. The relationship between treatment accessibility and preference amongst out-of-treatment individuals who engage in non-medical prescription opioid use. Drug Alcohol Depend. 2017;180:279–285.